Search

Displaying results 3581 - 3590 of 10000 in total
  1. Drug

    Zatebradine

    go.drugbank.com/drugs/DB21228
    Experimental

    Zatebradine is a small molecule drug. The usage of the INN stem '-bradine' in the name indicates that Zatebradine is a bradycardic agent. Zatebradine has a monoisotopic molecular weight of 456.26 Da.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Loracarbef

    go.drugbank.com/drugs/DB00447
    ApprovedWithdrawn

    Loracarbef is a carbacephem antibiotic sometimes grouped together with the second-generation cephalosporin antibiotics. It is marketed under the trade name Lorabid.

  3. Drug

    C326

    go.drugbank.com/drugs/DB06017
    Experimental

    The drug is composed of an IL-6–binding trimer and a IgG-binding domain. … C326 is an investigational compound under investigation in clinical trial NCT00353756 (Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohn's Disease) for the treatment

  4. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. … Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3).

    Synonyms: N-methyl-2-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]sulfanyl]benzamideCategories: UGT1A1 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  5. Drug

    Propacetamol

    go.drugbank.com/drugs/DB09288
    Investigational

    [A7892] It is not available in the United States but this prodrug has been widely used in other countries such as France since 1985.[L1505] … Propacetamol is a parenteral formulation of paracetamol and thus, it is a prodrug that is completely hydrolyzed to paracetamol.

  6. Drug

    Metenkefalin

    go.drugbank.com/drugs/DB12668
    Investigational

    Metenkefalin is an endogenous opioid and beta-endorphin.[A203225] It has been shown to reduce chromosomal abberations in patients with multiple sclerosis. … [A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877]

  7. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … In the phase II clinical trial called SYNCHRONY, with type II diabetic patients, aleglitazar was able to control both lipid and glucose levels in a synergistic manner while also having limited side effects

  8. Drug

    Hexylcaine

    go.drugbank.com/drugs/DB00473
    ApprovedWithdrawn

    Hexylcaine has been discontinued in the US market. … Hexylcaine hydrochloride is also known as cyclaine and osmocaine. It is a short acting local anesthetic that acts through inhibition of sodium channels.

  9. Drug

    Zongertinib

    go.drugbank.com/drugs/DB18762
    ApprovedInvestigational

    Zongertinib is a selective, irreversible tyrosine kinase inhibitor that targets human epidermal growth factor receptor 2 (HER2). … [L53873,A274363] It covalently binds to the HER2 receptor, including exon 20 insertions, and inhibits downstream signaling pathways while sparing wild-type epidermal growth factor receptor (EGFR), which

  10. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. … As a result, Sanofi stopped the development of the drug.

    Categories: Factor Xa Inhibitors